JustInvest LLC Invests $357,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

JustInvest LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, Holdings Channel reports. The firm acquired 10,730 shares of the biopharmaceutical company’s stock, valued at approximately $357,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in shares of TG Therapeutics by 2.2% during the 2nd quarter. ProShare Advisors LLC now owns 33,256 shares of the biopharmaceutical company’s stock worth $1,290,000 after purchasing an additional 711 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of TG Therapeutics by 13.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 6,594 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 800 shares during the period. First Mercantile Trust Co. boosted its holdings in shares of TG Therapeutics by 40.7% during the 2nd quarter. First Mercantile Trust Co. now owns 2,767 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 801 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of TG Therapeutics by 1.7% during the 2nd quarter. Principal Financial Group Inc. now owns 53,424 shares of the biopharmaceutical company’s stock worth $2,072,000 after buying an additional 877 shares during the period. Finally, Blair William & Co. IL boosted its holdings in shares of TG Therapeutics by 9.8% during the 2nd quarter. Blair William & Co. IL now owns 11,250 shares of the biopharmaceutical company’s stock worth $436,000 after buying an additional 1,000 shares during the period. Institutional investors own 67.59% of the company’s stock.

Several analysts recently commented on TGTX shares. The Goldman Sachs Group reduced their target price on shares of TG Therapeutics from $26.00 to $13.00 and set a “sell” rating for the company in a report on Wednesday, December 1st. HC Wainwright reduced their target price on shares of TG Therapeutics from $84.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, December 1st. Evercore ISI reduced their target price on shares of TG Therapeutics from $55.00 to $36.00 and set an “outperform” rating for the company in a report on Wednesday, December 1st. Finally, Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Hold” and an average price target of $54.75.

In other news, CEO Michael S. Weiss sold 37,549 shares of the company’s stock in a transaction that occurred on Tuesday, January 4th. The shares were sold at an average price of $19.20, for a total transaction of $720,940.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sean A. Power sold 75,312 shares of the company’s stock in a transaction that occurred on Tuesday, January 4th. The stock was sold at an average price of $19.20, for a total transaction of $1,445,990.40. The disclosure for this sale can be found here. Corporate insiders own 10.20% of the company’s stock.

NASDAQ TGTX opened at $15.69 on Friday. The firm has a 50-day moving average price of $20.73 and a two-hundred day moving average price of $27.82. TG Therapeutics, Inc. has a 12-month low of $12.62 and a 12-month high of $56.50. The company has a market capitalization of $2.22 billion, a P/E ratio of -5.94 and a beta of 1.93.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.09). TG Therapeutics had a negative return on equity of 82.68% and a negative net margin of 7,784.36%. The firm had revenue of $2.03 million for the quarter, compared to the consensus estimate of $3.23 million. During the same period last year, the company posted ($0.73) EPS. As a group, research analysts forecast that TG Therapeutics, Inc. will post -2.54 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Read More: Quick Ratio

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.